Clinical trials: Proliferative Diabetic Retinopathy
Proliferative Diabetic Retinopathy, Angiogenesis
Fractalkine, a CX3C Chemokine, Act as a Mediator of Ocular Angiogenesis
Fractalkine (FKN) is a chemoattractant and adhesion molecule for leukocytes. Angiogenic effect of FKN also has been reported. We investigate FKN-mediated angiogenesis in ocular angiogenic disorders.
- Trial name
- NCT00728598
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- National Taiwan University Hospital
NPDR - Non Proliferative Diabetic Retinopathy, Diabetes Mellitus, Type 2
Characterization of Retinal Disease Progression in Eyes With Non Proliferative Diabetic Retinopathy in Diabetes Type 2 Using Non-invasive Procedures (CHART)
To identify biomarkers, obtained using non-invasive procedures, that can predict disease progression and progression to sight-threatening stages of the disease and to characterize the retinal changes that occur in Non…
- Conditions
- NPDR - Non Proliferative Diabetic Retinopathy, Diabetes Mellitus, Type 2, Retinal Disease
- Trial name
- CHART (NCT04636307)
- Testing
- Biomarkers
- Where
- 5 sites in France, Italy and 1 more
- Volunteers
- 202 people
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
Diabetic Retinopathy With Premacular Hemorrhage
Intravitreal Injection of Bevacizumab and Gas for Diabetic Premacular Hemorrhage With Active Fibrovascular Proliferation
Diabetic premacular hemorrhage occurs when blood from preretinal neovascular tissue is entrapped between the retina and the posterior hyaloid in the macular area.
- Trial name
- NCT00673296
- Testing
- Intravitreal Bevacizumab
- Where
- Taiwan
- Volunteers
- 6 people
- Sponsor
- National Taiwan University Hospital
Rubeosis Iridis, Proliferative Diabetic Retinopathy
Use of Ranibizumab to Treat Rubeosis in Diabetics Prior to Cataract Surgery
The purpose of this study was to determine the safety of ranibizumab: a) as a surgical adjunct during cataract surgery in subjects with proliferative diabetic retinopathy (PDR) induced rubeosis and, b) in treatment of…
- Trial name
- NCT01069341
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Bhagat, Neelakshi, M.D., M.P.H.
Retinal Detachment, Diabetic Retinopathy
Avastin for PDR (Proliferative Diabetic Retinopathy)
The purpose of this study is to determine the effect of anti-VEGF drug (Avastin) adminstration in eyes prior to surgical treatment for Traction retinal detachment (TRD) in patients with Proliferative Diabetic Retinopathy (PDR).
- Trial name
- PDR (NCT01270542)
- Testing
- Avastin (bevacizumab)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Southern California
Non-proliferative Diabetic Retinopathy
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)
This Phase 3 Study will evaluate the efficacy and safety of KSI-301 in participants with moderately severe to severe non-proliferative diabetic retinopathy (NPDR).
- Trial name
- GLOW (NCT05066230)
- Testing
- KSI-301
- Where
- 61 sites in United States, Czechia and 5 more
- Volunteers
- 253 people
- Sponsor
- Kodiak Sciences Inc
Proliferative Diabetic Retinopathy
Comparison of Surgery Outcome Between Preoperative IVR and Intraoperative IVR in PPV for PDR
Proliferative diabetic retinopathy (PDR) is the most common causes of irreversible blindness in diabetic retinopathy (DR).Intravitreal injection of anti-VEGF drugs is a good adjunct to vitreous surgery for severe PDR.
- Trial name
- NCT05408416
- Testing
- preoperative group and intraoperative group
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Peking University People's Hospital
Diabetic Retinopathy, Posterior Vitreous Detachment
A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR
The purpose of this study is to assess the efficacy and safety of up to 3 intravitreal injections of ocriplasmin (0.0625mg or 0.125mg), in subjects with moderate to very severe non-proliferative diabetic retinopathy (NPDR), to…
- Conditions
- Diabetic Retinopathy, Posterior Vitreous Detachment, Disease Progression
- Trial name
- CIRCLE (NCT02681809)
- Testing
- ocriplasmin 0.0625mg, ocriplasmin 0.125mg
- Where
- 38 sites in United States, Czechia and 7 more
- Volunteers
- 48 people
- Sponsor
- ThromboGenics
Non-Proliferative Diabetic Retinopathy, Cataract
Nepafenac Once Daily for Macular Edema - Study 2
The purpose of this study is to demonstrate superiority of Nepafenac Ophthalmic Suspension, 0.3% dosed once daily relative to Nepafenac Vehicle based upon clinical outcomes among diabetic participants following cataract surgery.
- Trial name
- NCT01872611
- Testing
- Nepafenac Ophthalmic Suspension, 0.3%, Vehicle, Prednisolone acetate
- Volunteers
- 819 people
- Sponsor
- Alcon Research
Vitreous Detachment, Diabetic Retinopathy
Assessment of Intravitreous Injections of Vitrase for Inducing Posterior Vitreous Detachment
The purpose of this study is to assess the efficacy of intravitreous injections of Vitrase to induce posterior vitreous detachment(PVD) in subjects with moderate to severe non-proliferative diabetic retinopathy.
- Trial name
- NCT00198471
- Testing
- Vitrase
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Bausch & Lomb Incorporated
Pain
Oral Diclofenac for Retinal Photocoagulation in Diabetic Retinopathy
The purpose of this study was to evaluate the analgesic effect of oral potassium diclofenac in patients with proliferative diabetic retinopathy submitted to retinal photocoagulation.
- Trial name
- NCT01009021
- Testing
- potassium diclofenac
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- University of Sao Paulo
Proliferative Diabetic Retinopathy, Tractional Retinal Detachment
Conbercept Injection in Treatment of Severe Proliferative Diabetic Retinopathy
To evaluate efficacy of different intravitreal Conbercept injection therapy in the treatment of severe proliferative diabetic retinopathy.
- Trial name
- NCT02816710
- Testing
- Conbercept
- Where
- China
- Volunteers
- 112 people
- Sponsor
- Ruijin Hospital
Epiretinal Membrane, Macular Hole
Association of Lutein, Zeaxanthin and Brilliant Blue in Chromovitrectomy
The aim of this study is to test the efficacy of the combination of dye Lutein, Zeaxanthin and brilliant blue to stain the internal limiting membrane as well as the epiretinal membranes during the Vitrectomy surgery.
- Conditions
- Epiretinal Membrane, Macular Hole, Proliferative Diabetic Retinopathy
- Trial name
- NCT01627977
- Testing
- Dye of Lutein, Zeaxanthin and Brilliant Blue
- Where
- Brazil
- Volunteers
- 18 people
- Sponsor
- Federal University of São Paulo
Proliferative Diabetic Retinopathy
Conbercept vs Panretinal Photocoagulation for the Management of Proliferative Diabetic Retinopathy
Panretinal photocoagulation (PRP) has been the standard treatment for Proliferative diabetic retinopathy (PDR) since the Diabetic Retinopathy Study demonstrated its benefit nearly 40 years ago,but PRP has inevitable adverse…
- Trial name
- NCT02911311
- Testing
- intravitreal injection of conbercept, PRP
- Where
- China
- Volunteers
- 226 people
- Sponsor
- Sun Yat-sen University
Diabetic Retinopathy
Extension Study of Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy
This multicenter, open-label extension study will evaluate the long-term tolerability and safety for patients completing study CSMS995 0802.
- Trial name
- NCT00248131
- Testing
- Octreotide acetate in microspheres
- Volunteers
- 260 people
- Sponsor
- Novartis Pharmaceuticals
Proliferative Diabetic Retinopathy
Surgical Outcomes for Proliferative Diabetic Retinopathy by Preoperative Glycemic Control and Renal Function
The surgical outcomes of 25-gauge vitrectomy for proliferative diabetic retinopathy has been evaluated by preoperative glycemic control and renal function
- Trial name
- NCT03522311
- Testing
- Vitrectomy
- Volunteers
- 251 people
- Sponsor
- Kyorin University
Neovascular
Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters
Is it possible to do a panretinal photocoagulation for proliferative diabetic retinopathy in a single session using low fluence parameters?
- Trial name
- PFC (NCT01023698)
- Testing
- laser photocoagulation
- Volunteers
- 30 people
- Sponsor
- Asociación para Evitar la Ceguera en México
Non-proliferative Diabetic Retinopathy
Intravitreal Bevacizumab for Nonproliferative Diabetic Retinopathy
In this randomized clinical trial, 100 eyes with nonproliferative diabetic retinopathy will be included and divided randomly into 2 groups: Intravitreal Bevacizumab group (50 eyes) that receive 6 bimonthly intravitreal…
- Trial name
- NCT04511715
- Testing
- Intravitreal Bevacizumab IVB, Follow-up with regular examination for determination of DR progression
- Volunteers
- 100 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Wet AMD, Macular Oedema
Intravitreal Bevacizumab for Retinal Disorders
Bevacizumab is an anti-VEGF agent used in approved for use in metastatic colorectal carcinoma (FDA Approved). This study analyzes the safety and efficacy of off-label Intravitreal Injection of bevacizumab (Avastin) for CNVM…
- Conditions
- Wet AMD, Macular Oedema, Proliferative Diabetic Retinopathy
- Trial name
- NCT00403026
- Testing
- Bevacizumab ( Avastin)
- Where
- India
- Volunteers
- 150 people
- Sponsor
- Narayana Nethralaya
Diabetic Macular Edema
Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE)
This study is a Phase I/II, multicenter, randomized, study of the efficacy and safety of ranibizumab injection monotherapy verses a duel therapy of 0.3mg ranibizumab combined with ultra wide, 200° field angiography guided pan…
- Trial name
- DAVE (NCT01552408)
- Testing
- 0.3 mg ranibizumab, Targeted Pan Retinal Photocoagulation
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- David M. Brown, M.D.